Opioid receptors are a group of inhibitory G protein-coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. The opioid receptors are ~40% identical to somatostatin receptors (SSTRs). Opioid receptors are distributed widely in the brain, in the spinal cord, on peripheral neurons, and digestive tract.
By the mid-1960s, it had become apparent from pharmacologic studies that opiate drugs were likely to exert their actions at specific receptor sites, and that there were likely to be multiple such sites. Early studies had indicated that opiates appeared to accumulate in the brain. The receptors were first identified as specific molecules through the use of binding studies, in which opiates that had been labeled with radioisotopes were found to bind to brain membrane homogenates. The first such study was published in 1971, using 3H-levorphanol. In 1973, Candace Pert and Solomon H. Snyder published the first detailed binding study of what would turn out to be the μ opioid receptor, using 3H-naloxone. That study has been widely credited as the first definitive finding of an opioid receptor, although two other studies followed shortly after.
Purification of the receptor further verified its existence. The first attempt to purify the receptor involved the use of a novel opioid receptor antagonist called chlornaltrexamine that was demonstrated to bind to the opioid receptor. Caruso later purified the detergent-extracted component of rat brain membrane that eluted with the specifically bound 3H-chlornaltrexamine.
There are four major subtypes of opioid receptors. OGFr was originally discovered and named as a new opioid receptor zeta (ζ). However it was subsequently found that it shares little sequence similarity with the other opioid receptors, and has quite different function.
|κ1, κ2, κ3|
|μ1, μ2, μ3||μ1:
(I). Name based on order of discovery
The opioid receptor family originated from two duplication events of a single ancestral opioid receptor early in vertebrate evolution. Phylogenetic analysis demonstrates that the family of opioid receptors was already present at the origin of jawed vertebrates over 450 million years ago. In humans, this paralogon resulting from a double tetraploidization event resulted in the receptor genes being located on chromosomes 1, 6, 8, and 20. Tetraploidization events often result in the loss of one or more of the duplicated genes, but in this case, nearly all species retain all four opioid receptors, indicating important and specific function. The receptor families delta, kappa, and mu demonstrate 55–58% identity to one another, and a 48–49% homology to the nociceptin receptor. Taken together, this indicates that the NOP receptor gene, OPRL1, has equal evolutionary origin, but a higher mutation rate, than the other receptor genes.
The endogenous opioid system is thought to be important in mediating complex social behaviors involved in the formation of stable, emotionally committed relationships. Social attachment was demonstrated to be mediated by the opioid system through experiments administering morphine and naltrexone, an opioid agonist and antagonist, to juvenile guinea pigs. The agonist decreased the preference of the juvenile to be near the mother and reduced distress vocalization whereas the antagonist had the opposite effects. Experiments were corroborated in dogs, chicks, and rats confirming the evolutionary importance of opioid signaling in these behaviors. Researchers have also found that systemic naltrexone treatment of female prairie voles during initial exposure to a male reduced subsequent mating bouts and nonsexual socialization with this familiar partner, when a choice test including a novel male was performed afterwards. This points to a role for opioid receptors in mating behaviors.
There is evidence that human-specific opioid-modulated cognitive traits rely not on coding differences for the receptors or ligands, which display 99% homology with primates, but instead are due to regulatory changes in expression levels that are specifically selected for.
The receptors were named using the first letter of the first ligand that was found to bind to them. Morphine was the first chemical shown to bind to "mu" receptors. The first letter of the drug morphine is m, rendered as the corresponding Greek letter μ. In similar manner, a drug known as ketocyclazocine was first shown to attach itself to "κ" (kappa) receptors, while the "δ" (delta) receptor was named after the mouse vas deferens tissue in which the receptor was first characterised. An additional opioid receptor was later identified and cloned based on homology with the cDNA. This receptor is known as the nociceptin receptor or ORL1 (opiate receptor-like 1).
The opioid receptor types are nearly 70% identical, with the differences located at the N and C termini. The μ receptor is perhaps the most important. It is thought that the G protein binds to the third intracellular loop of all opioid receptors. Both in mice and humans, the genes for the various receptor subtypes are located on separate chromosomes.
Separate opioid receptor subtypes have been identified in human tissue. Research has so far failed to identify the genetic evidence of the subtypes, and it is thought that they arise from post-translational modification of cloned receptor types.
An IUPHAR subcommittee has recommended that appropriate terminology for the 3 classical (μ, δ, κ) receptors, and the non-classical (nociceptin) receptor, should be MOP ("Mu OPiate receptor"), DOP, KOP and NOP respectively.
Sigma (σ) receptors were once considered to be opioid receptors due to the antitussive actions of many opioid drugs' being mediated via σ receptors, and the first selective σ agonists being derivatives of opioid drugs (e.g., allylnormetazocine). However, σ receptors were found to not be activated by endogenous opioid peptides, and are quite different from the other opioid receptors in both function and gene sequence, so they are now not usually classified with the opioid receptors.
The existence of further opioid receptors (or receptor subtypes) has also been suggested because of pharmacological evidence of actions produced by endogenous opioid peptides, but shown not to be mediated through any of the four known opioid receptor subtypes. The existence of receptor subtypes or additional receptors other than the classical opioid receptors (μ, δ, κ) has been based on limited evidence, since only three genes for the three main receptors have been identified. The only one of these additional receptors to have been definitively identified is the zeta (ζ) opioid receptor, which has been shown to be a cellular growth factor modulator with met-enkephalin being the endogenous ligand. This receptor is now most commonly referred to as the opioid growth factor receptor (OGFr).
ε opioid receptor
Another postulated opioid receptor is the ε opioid receptor. The existence of this receptor was suspected after the endogenous opioid peptide beta-endorphin was shown to produce additional actions that did not seem to be mediated through any of the known opioid receptors. Activation of this receptor produces strong analgesia and release of met-enkephalin; a number of widely used opioid agonists, such as the μ agonist etorphine and the κ agonist bremazocine, have been shown to act as agonists for this effect (even in the presence of antagonists to their more well known targets), while buprenorphine has been shown to act as an epsilon antagonist. Several selective agonists and antagonists are now available for the putative epsilon receptor; however, efforts to locate a gene for this receptor have been unsuccessful, and epsilon-mediated effects were absent in μ/δ/κ "triple knockout" mice, suggesting the epsilon receptor is likely to be either a splice variant derived from alternate post-translational modification, or a heteromer derived from hybridization of two or more of the known opioid receptors.
Mechanism of activation
Opioid receptors are a type of G protein–coupled receptor (GPCR). These receptors are distributed throughout the central nervous system and within the peripheral tissue of neural and non-neural origin. They are also located in high concentrations in the Periaqueductal gray, Locus coeruleus, and the Rostral ventromedial medulla. The receptors are responsible for analgesia, and consist of an extracellular amino acid N-terminus, seven trans-membrane helical loops, three extracellular loops, three intracellular loops, and an intracellular carboxyl C-terminus. The three extracellular loops of the GPCR form parts of the pocket in which signalling molecules can bind, to initiate a response. G proteins are specialised proteins whereby the nucleotides Guanosine diphosphate (GDP), and Guanosine triphosphate (GTP) bind to. They are classified as heterotrimeric, meaning they contain three different sub-units, which include an alpha (α) subunit, a beta (β) subunit, and a gamma (γ) sub-unit. The gamma and beta sub-units are permanently bound together, producing a single Gβγ sub-unit. Heterotrimeric G proteins act as ‘molecular switches’, which play a key role in signal transduction, because they relay information from activated receptors to appropriate effector proteins. All G protein α sub-units contain palmitate, which is a 16-carbon saturated fatty acid, that is attached near the N-terminus through a labile, reversible thioester linkage to a cysteine amino acid. It is this palmitoylation that allows the G protein to interact with membrane phospholipids due to the hydrophobic nature of the alpha sub-units. The gamma sub-unit is also lipid modified and can attach to the plasma membrane as well. These properties of the two sub-units, allow the opioid receptor's G protein to permanently interact with the membrane via lipid anchors.
When an agonistic ligand binds to the opioid receptor, a conformational change occurs, and the GDP molecule is released from the Gα sub-unit. This mechanism is complex, and is a major stage of the signal transduction pathway. When the GDP molecule is attached, the Gα sub-unit is in its inactive state, and the nucleotide-binding pocket is closed off inside the protein complex. However, upon ligand binding, the receptor switches to an active conformation, and this is driven by intermolecular rearrangement between the trans-membrane helices. The receptor acitvation releases an ‘ionic lock’ which holds together the cytoplasmic sides of transmembrane helices three and six, causing them to rotate. This conformational change exposes the intracellular receptor domains at the cytosolic side, which further leads to the activation of the G protein. When the GDP molecule dissociates from the Gα sub-unit, a GTP molecule binds to the free nucleotide-binding pocket, and the G protein becomes active. A Gα(GTP) complex is formed, which has a weaker affinity for the Gβγ sub-unit than the Gα(GDP) complex, causing the Gα sub-unit to separate from the Gβγ sub-unit, forming two sections of the G protein. The sub-units are now free to interact with effector proteins; however, they are still attached to the plasma membrane by lipid anchors. After binding, the active G protein sub-units diffuses within the membrane and acts on various intracellular effector pathways. This includes inhibiting neuronal adenylate cyclase activity, as well as increasing membrane hyper-polarisation. When the adenylyl cyclase enzyme complex is stimulated, it results in the formation of Cyclic Adenosine 3', 5'-Monophosphate (cAMP), from Adenosine 5' Triphosphate (ATP). cAMP acts as a secondary messenger, as it moves from the plasma membrane into the cell and relays the signal.
cAMP binds to, and activates cAMP-dependent protein kinase A (PKA), which is located intracellularly in the neuron. The PKA consists of a holoenzyme - it is a compound which becomes active due to the combination of an enzyme with a coenzyme. The PKA enzyme also contains two catalytic PKS-Cα subunits, and a regulator PKA-R subunit dimer. The PKA holoenzyme is inactive under normal conditions, however, when cAMP molecules that are produced earlier in the signal transduction mechanism combine with the enzyme, PKA undergoes a conformational change. This activates it, giving it the ability to catalyse substrate phosphorylation. CREB (cAMP response element binding protein) belongs to a family of transcription factors and is positioned in the nucleus of the neuron. When the PKA is activated, it phosphorylates the CREB protein (adds a high energy phosphate group) and activates it. The CREB protein binds to cAMP response elements CRE, and can either increase or decrease the transcription of certain genes. The cAMP/PKA/CREB signalling pathway described above is crucial in memory formation and pain modulation. It is also significant in the induction and maintenance of long-term potentiation, which is a phenomenon that underlies synaptic plasticity - the ability of synapses to strengthen or weaken over time.
Voltage-gated dependent calcium channel, (VDCCs), are key in the depolarisation of neurons, and play a major role in promoting the release of neurotransmitters. When agonists bind to opioid receptors, G proteins activate and dissociate into their constituent Gα and Gβγ sub-units. The Gβγ sub-unit binds to the intracellular loop between the two trans-membrane helices of the VDCC. When the sub-unit binds to the voltage-dependent calcium channel, it produces a voltage-dependent block, which inhibits the channel, preventing the flow of calcium ions into the neuron. Embedded in the cell membrane is also the G protein-coupled inwardly-rectifying potassium channel. When a Gβγ or Gα(GTP) molecule binds to the C-terminus of the potassium channel, it becomes active, and potassium ions are pumped out of the neuron. The activation of the potassium channel and subsequent deactivation of the calcium channel causes membrane hyperpolarization. This is when there is a change in the membrane’s potential, so that it becomes more negative. The reduction in calcium ions causes a reduction neurotransmitter release because calcium is essential for this event to occur. This means that neurotransmitters such as glutamate and substance P cannot be released from the presynaptic terminal of the neurons. These neurotransmitters are vital in the transmission of pain, so opioid receptor activation reduces the release of these substances, thus creating a strong analgesic effect.
Some forms of mutations in δ-opioid receptors have resulted in constant receptor activation.
- Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M (December 1996). "International Union of Pharmacology. XII. Classification of opioid receptors". Pharmacol. Rev. 48 (4): 567–592. PMID 8981566.
- Janecka A, Fichna J, Janecki T (2004). "Opioid receptors and their ligands". Curr. Top. Med. Chem. 4 (1): 1–17. doi:10.2174/1568026043451618. PMID 14754373.
- Waldhoer M, Bartlett SE, Whistler JL (2004). "Opioid receptors". Annu. Rev. Biochem. 73: 953–990. doi:10.1146/annurev.biochem.73.011303.073940. PMID 15189164.
- Martin, W. R. (December 1967). "Opioid antagonists". Pharmacol. Rev. 19 (4): 463–521. PMID 4867058. Retrieved December 29, 2013.
- Ingoglia NA, Dole VP (1970). "Localization of d and l-methadone after intraventricular injection into rat brains". J. Pharmacol. Exp. Ther. 175 (1): 84–87. PMID 5471456.
- Goldstein A, Lowney LI, Pal BK (August 1971). "Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain". Proc. Natl. Acad. Sci. U.S.A. 68 (8): 1742–7. doi:10.1073/pnas.68.8.1742. PMC 389284. PMID 5288759.
- Pert CB, Snyder SH (March 1973). "Opiate receptor: demonstration in nervous tissue". Science. 179 (4077): 1011–4. doi:10.1126/science.179.4077.1011. PMID 4687585.
- Terenius L (1973). "Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex". Acta Pharmacol. Toxicol. (Copenh.). 32 (3): 317–20. doi:10.1111/j.1600-0773.1973.tb01477.x. PMID 4801733.
- Simon EJ, Hiller JM, Edelman I (July 1973). "Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate". Proc. Natl. Acad. Sci. U.S.A. 70 (7): 1947–9. doi:10.1073/pnas.70.7.1947. PMC 433639. PMID 4516196.
- Caruso TP, Takemori AE, Larson DL, Portoghese PS (April 1979). "Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity". Science. 204 (4390): 316–8. doi:10.1126/science.86208. PMID 86208.
- Caruso TP, Larson DL, Portoghese PS, Takemori AE (December 1980). "Isolation of selective 3H-chlornaltrexamine-bound complexes, possible opioid receptor components in brains of mice". Life Sciences. 27 (22): 2063–9. doi:10.1016/0024-3205(80)90485-3. PMID 6259471.
- Corbett AD, Henderson G, McKnight AT, Paterson SJ (2006). "75 years of opioid research: the exciting but vain quest for the Holy Grail". Br. J. Pharmacol. 147 Suppl 1 (Suppl 1): S153–62. doi:10.1038/sj.bjp.0706435. PMC 1760732. PMID 16402099.
- Stein C, Schäfer M, Machelska H (August 2003). "Attacking pain at its source: new perspectives on opioids". Nat. Med. 9 (8): 1003–8. doi:10.1038/nm908. PMID 12894165.
- Fine PG, Portenoy RK (2004). "Chapter 2: The Endogenous Opioid System" (PDF). A Clinical Guide to Opioid Analgesia. McGraw Hill.
- Portoghese PS, Lunzer MM (2003). "Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord". Eur. J. Pharmacol. 467 (1–3): 233–4. doi:10.1016/s0014-2999(03)01599-1. PMID 12706480.
- Stevens CW (2009). "The evolution of vertebrate opioid receptors". Front Biosci. 14: 1247–69. PMC 3070387. PMID 19273128.
- Furay AR, Neumaier JF (October 2011). "Opioid receptors: binding that ties". Neuropsychopharmacology. 36 (11): 2157–8. doi:10.1038/npp.2011.147. PMC 3176578. PMID 21918519.
- Burkett JP, Spiegel LL, Inoue K, Murphy AZ, Young LJ (October 2011). "Activation of μ-opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles". Neuropsychopharmacology. 36 (11): 2200–10. doi:10.1038/npp.2011.117. PMC 3176565. PMID 21734650.
- Cruz-Gordillo P, Fedrigo O, Wray GA, Babbitt CC (2010). "Extensive changes in the expression of the opioid genes between humans and chimpanzees". Brain Behav. Evol. 76 (2): 154–62. doi:10.1159/000320968. PMID 21079395.
- Rockman MV, Hahn MW, Soranzo N, Zimprich F, Goldstein DB, Wray GA (December 2005). "Ancient and recent positive selection transformed opioid cis-regulation in humans". PLoS Biol. 3 (12): e387. doi:10.1371/journal.pbio.0030387. PMC 1283535. PMID 16274263.
- Aggrawal A (May 1, 1995). "Opium: the king of narcotics". Opioids: past, present and future. BLTC Research. Archived from the original on May 26, 2012. Retrieved December 29, 2013.
- Lord JA, Waterfield AA, Hughes J, Kosterlitz HW (1977). "Endogenous opioid peptides: multiple agonists and receptors". Nature. 267 (5611): 495–9. doi:10.1038/267495a0. PMID 195217.
- Lemke, Thomas L., Williams, David H., Foye, William O. (2002). "Opioid Analgesics; Fries, DS". Foye's principles of medicinal chemistry. Hagerstown, MD: Lippincott Williams & Wilkins. ISBN 978-0-683-30737-5.
- Girdlestone D (October 2000). "Opioid receptors; Cox BM, Chavkin C, Christie MJ, Civelli O, Evans C, Hamon MD, et al.". The IUPHAR Compendium of Receptor Characterization and Classification (2nd ed.). London: IUPHAR Media. pp. 321–333.
- "Opioid receptors". IUPHAR Database. International Union of Pharmacology (2008-08-01).
- Dietis N, Rowbotham D, Lambert D (May 2011). "Opioid receptor subtypes: fact or artifact?". British Journal of Anaesthesia. 107 (1): 8–18. doi:10.1093/bja/aer115. PMID 21613279.
- Grevel J, Yu V, Sadée W (May 1985). "Characterization of a labile naloxone binding site (lambda site) in rat brain". J. Neurochem. 44 (5): 1647–56. doi:10.1111/j.1471-4159.1985.tb08808.x. PMID 2985759.
- Mizoguchi H, Narita M, Nagase H, Tseng LF (October 2000). "Activation of G-proteins in the mouse pons/medulla by beta-endorphin is mediated by the stimulation of mu- and putative epsilon-receptors". Life Sci. 67 (22): 2733–43. doi:10.1016/S0024-3205(00)00852-3. PMID 11105989.
- Wollemann M, Benyhe S (June 2004). "Non-opioid actions of opioid peptides". Life Sci. 75 (3): 257–70. doi:10.1016/j.lfs.2003.12.005. PMID 15135648.
- Zagon IS, Verderame MF, Allen SS, McLaughlin PJ (February 2000). "Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans". Brain Res. 856 (1–2): 75–83. doi:10.1016/S0006-8993(99)02330-6. PMID 10677613.
- Zagon IS, Verderame MF, McLaughlin PJ (February 2002). "The biology of the opioid growth factor receptor (OGFr)". Brain Res. Brain Res. Rev. 38 (3): 351–76. doi:10.1016/S0165-0173(01)00160-6. PMID 11890982.
- Wüster M, Schulz R, Herz A (December 1979). "Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors". Neuroscience Letters. 15 (2–3): 193–8. doi:10.1016/0304-3940(79)96112-3. PMID 231238.
- Schulz R, Wüster M, Herz A (March 1981). "Pharmacological characterization of the epsilon-opiate receptor". The Journal of Pharmacology and Experimental Therapeutics. 216 (3): 604–6. PMID 6259326.
- Narita M, Tseng LF (March 1998). "Evidence for the existence of the beta-endorphin-sensitive "epsilon-opioid receptor" in the brain: the mechanisms of epsilon-mediated antinociception". Japanese Journal of Pharmacology. 76 (3): 233–53. doi:10.1254/jjp.76.233. PMID 9593217.
- Fujii H, Narita M, Mizoguchi H, Murachi M, Tanaka T, Kawai K, Tseng LF, Nagase H (August 2004). "Drug design and synthesis of epsilon opioid receptor agonist: 17-(cyclopropylmethyl)-4,5alpha-epoxy-3,6beta-dihydroxy-6,14-endoethenomorphinan-7alpha-(N-methyl-N-phenethyl)carboxamide (TAN-821) inducing antinociception mediated by putative epsilon opioid receptor". Bioorganic & Medicinal Chemistry. 12 (15): 4133–45. doi:10.1016/j.bmc.2004.05.024. PMID 15246090.
- Fujii H, Nagase H (2006). "Rational drug design of selective epsilon opioid receptor agonist TAN-821 and antagonist TAN-1014". Current Medicinal Chemistry. 13 (10): 1109–18. doi:10.2174/092986706776360851. PMID 16719773.
- Contet C, Matifas A, Kieffer BL (May 2004). "No evidence for G-protein-coupled epsilon receptor in the brain of triple opioid receptor knockout mouse". European Journal of Pharmacology. 492 (2–3): 131–6. doi:10.1016/j.ejphar.2004.03.056. PMID 15178356.
- Al-Hasani R, Bruchas MR (December 2011). "Molecular mechanisms of opioid receptor-dependent signaling and behavior". Anesthesiology. 115 (6): 1363–81. doi:10.1097/ALN.0b013e318238bba6. PMC 3698859. PMID 22020140.
- "Introduction to Essentials of Cell Biology | Learn Science at Scitable". www.nature.com. Retrieved 2017-11-08.
- Wedegaertner PB, Wilson PT, Bourne HR (January 1995). "Lipid modifications of trimeric G proteins". The Journal of Biological Chemistry. 270 (2): 503–6. doi:10.1074/jbc.270.2.503. PMID 7822269.
- Philip F, Sengupta P, Scarlata S (June 2007). "Signaling through a G Protein-coupled receptor and its corresponding G protein follows a stoichiometrically limited model". The Journal of Biological Chemistry. 282 (26): 19203–16. doi:10.1074/jbc.M701558200. PMID 17420253.
- Steer ML (November 1975). "Adenyl cyclase". Annals of Surgery. 182 (5): 603–9. doi:10.1097/00000658-197511000-00012. PMC 1344045. PMID 172034.
- Keshwani MM, Kanter JR, Ma Y, Wilderman A, Darshi M, Insel PA, Taylor SS (October 2015). "Mechanisms of cyclic AMP/protein kinase A- and glucocorticoid-mediated apoptosis using S49 lymphoma cells as a model system". Proceedings of the National Academy of Sciences of the United States of America. 112 (41): 12681–6. doi:10.1073/pnas.1516057112. PMC 4611605. PMID 26417071.
- Shao XM, Sun J, Jiang YL, Liu BY, Shen Z, Fang F, Du JY, Wu YY, Wang JL, Fang JQ (2016). "Inhibition of the cAMP/PKA/CREB Pathway Contributes to the Analgesic Effects of Electroacupuncture in the Anterior Cingulate Cortex in a Rat Pain Memory Model". Neural Plasticity. 2016: 1–16. doi:10.1155/2016/5320641. PMC 5206448. PMID 28090359.
- Yamada M, Inanobe A, Kurachi Y (December 1998). "G protein regulation of potassium ion channels". Pharmacological Reviews. 50 (4): 723–60. PMID 9860808.
- Kosten TR, George TP (July 2002). "The neurobiology of opioid dependence: implications for treatment". Science & Practice Perspectives. 1 (1): 13–20. doi:10.1151/spp021113. PMC 2851054. PMID 18567959.
- Befort K, Zilliox C, Filliol D, Yue S, Kieffer BL (June 1999). "Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII". J. Biol. Chem. 274 (26): 18574–81. doi:10.1074/jbc.274.26.18574. PMID 10373467.
- Fujita W, Gomes I, Devi LA (2014). "Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10". Br. J. Pharmacol. 171 (18): 4155–76. doi:10.1111/bph.12798. PMC 4241085. PMID 24916280.
- Opioid+Receptors at the US National Library of Medicine Medical Subject Headings (MeSH)
- "Opioid Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
- Corbett A, McKnight S, Henderson G. "Opioid Receptors". BLTC Research. Retrieved 2008-03-21.
- Lomize A, Lomize M, Pogozheva I. "Orientations of Proteins in Membranes (OPM) database". University of Michigan. Retrieved 2008-03-21.
- "Mu-opioid receptor model (inactive state) with antagonist". Retrieved 2008-03-21.
- "Mu-opioid receptor model in active state with agonist". Retrieved 2008-03-21.
- Guzman F. "Video lectures on opioid receptors". Pharmacology Corner. Retrieved 2012-07-30.